Quick Answer
Indivior Pharmaceuticals, Inc. reported R&D Expense of $106.00 million for fiscal year 2023.
Indivior Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2023 | $106.00M | +47.2% |
| 2022 | $72.00M | +38.5% |
| 2021 | $52.00M | — |
- Indivior Pharmaceuticals, Inc. showed an increase of +47.2% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2023 period, Indivior Pharmaceuticals, Inc.’s r&d expense has grown by 103.8% (from $52.00 million to $106.00 million).
- The most recent figure is from Indivior Pharmaceuticals, Inc.’s fiscal year 2023 report (Form 20-F), filed with the SEC on March 6, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: